# Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

> **NCT02231489** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42756493 Tablet
- **DRUG:** JNJ-42756493 Capsule
- **DRUG:** JNJ-61818549

## Key facts

- **NCT ID:** NCT02231489
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231489, "Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02231489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*